Repligen Corporation (RGEN)

Today's Latest Price: $181.43 USD

2.28 (1.27%)

Updated Nov 25 4:00pm

Add RGEN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Repligen Corp (RGEN) Price Targets From Analysts

Use the tables below to see what analysts covering Repligen Corp think about its future price and what recommendations they have for investors and traders.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
8 $241 $168 $211.5 $179.15 18.06%

RGEN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.11 8 0 1 0 0 9

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RGEN as an investment opportunity.

  • The percent of analysts bearish on the stock of RGEN is less than almost 100% of all US stocks.
  • RGEN has a greater average analyst price target than 97.9% of Pharmaceutical Products stocks.
  • Repligen Corp's percentage of analysts bullish on the stock is greater than 93.69% of stocks in the large market cap category.
  • Repligen Corp's number of analysts covering the stock is higher than 11.64% of stocks in the large market cap category.
  • RGEN has a higher upside potential (average analyst target price relative to current price) than 81.12% of stocks in the large market cap category.
  • The variance in analysts' estimates of RGEN is lower than 63.57% of Pharmaceutical Products stocks.
  • Repligen Corp's change in bullishness amongst analysts is less than almost 100% of all US stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Repligen Corp are ASND, ZLAB and LGND.

What is the outlook for RGEN? Use POWR Ratings for clearer insight into price direction.



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6547 seconds.